![Study flow diagram. Patients registered in the EBMT ProMISe database... | Download Scientific Diagram Study flow diagram. Patients registered in the EBMT ProMISe database... | Download Scientific Diagram](https://www.researchgate.net/publication/290168618/figure/fig1/AS:317263623278652@1452652950911/Study-flow-diagram-Patients-registered-in-the-EBMT-ProMISe-database-and-included-in-this.png)
Study flow diagram. Patients registered in the EBMT ProMISe database... | Download Scientific Diagram
![The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT | Bone Marrow Transplantation The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT | Bone Marrow Transplantation](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41409-023-01955-z/MediaObjects/41409_2023_1955_Fig1_HTML.png)
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT | Bone Marrow Transplantation
![CAR-T cell and the registry (a) timelines of CAR-T cell registrations... | Download Scientific Diagram CAR-T cell and the registry (a) timelines of CAR-T cell registrations... | Download Scientific Diagram](https://www.researchgate.net/profile/Eoin-Mcgrath/publication/342942734/figure/fig1/AS:914302814928897@1594998186856/CAR-T-cell-and-the-registry-a-timelines-of-CAR-T-cell-registrations-within-the-EBMT_Q320.jpg)
CAR-T cell and the registry (a) timelines of CAR-T cell registrations... | Download Scientific Diagram
![EBMT receives a regulatory qualification from the European Medicine Agency (EMA) on the use of its patient registry to support novel CAR T-cell therapies. — Tumorimmunology EBMT receives a regulatory qualification from the European Medicine Agency (EMA) on the use of its patient registry to support novel CAR T-cell therapies. — Tumorimmunology](https://images.squarespace-cdn.com/content/v1/550d3c8ce4b051bbaff3bba3/1551443949978-35HGVK9C5CQHGJQKKVTN/EBMT+logo.jpg?format=1000w)